# Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

> **NCT02337062** · PHASE3 · COMPLETED · sponsor: **Acacia Pharma Ltd** · enrollment: 1147 (actual)

## Conditions studied

- PONV

## Interventions

- **DRUG:** APD421
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02337062
- **Lead sponsor:** Acacia Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 1147 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337062, "Phase IIIb Study of APD421 in Combination as PONV Prophylaxis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02337062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*